The antineoplastic combinations market is projected to grow from USD 43,754.0 million in 2026 to USD 79,847.8 million by 2036, at a CAGR of 6.2%. Chemo + targeted will dominate with a 42.0% market share, while solid tumors will lead the applications segment with a 64.0% share.